Advice

following an abbreviated submission:

ledipasvir/sofosbuvir (HarvoniĀ®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years.

SMC restriction: genotype 1 and 4 CHC only.

SMC has previously accepted ledipasvir/sofosbuvir for use in adults with genotype 1 and 4 CHC.

Download full details45KB (PDF)

Download

Medicine details

Medicine name:
ledispavir / sofosbuvir (Harvoni)
SMC ID:
1343/18
Indication:
Treatment of chronic hepatitis C infection in adolescents aged 12 to < 18 years
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Infections
Submission type
Abbreviated submission
Status
Restricted
Date advice published:
11 June 2018